CMS
Banner Year for Blood-Based Cancer Screening in 2021, but Reimbursement and Utility Hurdles Loom
Premium
New companies claimed stakes during the year, established firms solidified their plans and data, and Grail launched the first genomic multi-cancer early detection test.
CMS Repeals Rule Aimed at Expediting Medicare Coverage for FDA Breakthrough Devices
The rule would have granted quicker Medicare coverage for up to four years for tests that had received breakthrough device designation from the FDA.
Palmetto Finalizes Medicare Coverage for MRD Cancer Testing
To receive coverage, the patient must have a personal history of cancer where the type and staging are within the intended use of the test.
The company has slightly extended its timeline for launching a Lyme disease test to focus on marketing its COVID assay for immunocompromised individuals.
Labs Ask Medicare Contractor to Refine Coverage Policy for 'Comprehensive' NGS Cancer Testing
Premium
National Government Services' proposal to broaden coverage of large sequencing panels for solid tumor patients is positive but may need clarification to ensure appropriate patient care.